Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wanlong Ma

Showing results (11-20 of 39) with videos related to

Pageof 4
Sort By:
Molecular Cancer Therapeutics|December 6, 2008
BCR-ABL alternative splicing as a common mechanism for imatinib resistance: evidence from molecular dynamics simulationsTai-Sung Lee, Wanlong Ma, Xi Zhang, et al.
Diagnostic Molecular Pathology : the American Journal of Surgical Pathology, Part B|February 18, 2011
MPL mutation profile in JAK2 mutation-negative patients with myeloproliferative disordersWanlong Ma, Xi Zhang, Xiuqiang Wang, et al.
Journal of Cancer|February 27, 2016
Predicting Prostate Biopsy Results Using a Panel of Plasma and Urine Biomarkers Combined in a Scoring SystemMaher Albitar, Wanlong Ma, Lars Lund, et al.
Oncotarget|February 18, 2017
Using high-sensitivity sequencing for the detection of mutations in BTK and PLCγ2 genes in cellular and cell-free DNA and correlation with progression in patients treated with BTK inhibitorsAdam Albitar, Wanlong Ma, Ivan DeDios, et al.
The Journal of Molecular Diagnostics : JMD|December 17, 2008
Mutation profile of JAK2 transcripts in patients with chronic myeloproliferative neoplasiasWanlong Ma, Hagop Kantarjian, Xi Zhang, et al.
Oncotarget|March 24, 2018
Correlation of <i>MET</i> gene amplification and <i>TP53</i> mutation with PD-L1 expression in non-small cell lung cancerMaher Albitar, Sucha Sudarsanam, Wanlong Ma, et al.
Genetic Testing and Molecular Biomarkers|June 2, 2016
Deep Sequencing of Cell-Free Peripheral Blood DNA as a Reliable Method for Confirming the Diagnosis of Myelodysplastic SyndromeFerras Albitar, Wanlong Ma, Kevin Diep, et al.
Molecular Cytogenetics|May 3, 2012
BCR-JAK2 fusion as a result of a translocation (9;22)(p24;q11.2) in a patient with CML-like myeloproliferative diseaseMohamed M Elnaggar, Sally Agersborg, Trilochan Sahoo, et al.
Journal of Cancer|September 14, 2017
A Multi-Center Prospective Study to Validate an Algorithm Using Urine and Plasma Biomarkers for Predicting Gleason ≥3+4 Prostate Cancer on BiopsyMaher Albitar, Wanlong Ma, Lars Lund, et al.
Neurological Research|June 20, 2012
Plasma ubiquitin-proteasome system profile in patients with multiple sclerosis: correlation with clinical features, neuroimaging, and treatment with interferon-beta-1bAlireza Minagar, Wanlong Ma, Xi Zhang, et al.
Pageof 4

Showing results (11-20 of 39) with videos related to

Sort By:
Pageof 4
Molecular Cancer Therapeutics|December 6, 2008
BCR-ABL alternative splicing as a common mechanism for imatinib resistance: evidence from molecular dynamics simulationsTai-Sung Lee, Wanlong Ma, Xi Zhang, et al.
Diagnostic Molecular Pathology : the American Journal of Surgical Pathology, Part B|February 18, 2011
MPL mutation profile in JAK2 mutation-negative patients with myeloproliferative disordersWanlong Ma, Xi Zhang, Xiuqiang Wang, et al.
Journal of Cancer|February 27, 2016
Predicting Prostate Biopsy Results Using a Panel of Plasma and Urine Biomarkers Combined in a Scoring SystemMaher Albitar, Wanlong Ma, Lars Lund, et al.
Oncotarget|February 18, 2017
Using high-sensitivity sequencing for the detection of mutations in BTK and PLCγ2 genes in cellular and cell-free DNA and correlation with progression in patients treated with BTK inhibitorsAdam Albitar, Wanlong Ma, Ivan DeDios, et al.
The Journal of Molecular Diagnostics : JMD|December 17, 2008
Mutation profile of JAK2 transcripts in patients with chronic myeloproliferative neoplasiasWanlong Ma, Hagop Kantarjian, Xi Zhang, et al.
Oncotarget|March 24, 2018
Correlation of <i>MET</i> gene amplification and <i>TP53</i> mutation with PD-L1 expression in non-small cell lung cancerMaher Albitar, Sucha Sudarsanam, Wanlong Ma, et al.
Genetic Testing and Molecular Biomarkers|June 2, 2016
Deep Sequencing of Cell-Free Peripheral Blood DNA as a Reliable Method for Confirming the Diagnosis of Myelodysplastic SyndromeFerras Albitar, Wanlong Ma, Kevin Diep, et al.
Molecular Cytogenetics|May 3, 2012
BCR-JAK2 fusion as a result of a translocation (9;22)(p24;q11.2) in a patient with CML-like myeloproliferative diseaseMohamed M Elnaggar, Sally Agersborg, Trilochan Sahoo, et al.
Journal of Cancer|September 14, 2017
A Multi-Center Prospective Study to Validate an Algorithm Using Urine and Plasma Biomarkers for Predicting Gleason ≥3+4 Prostate Cancer on BiopsyMaher Albitar, Wanlong Ma, Lars Lund, et al.
Neurological Research|June 20, 2012
Plasma ubiquitin-proteasome system profile in patients with multiple sclerosis: correlation with clinical features, neuroimaging, and treatment with interferon-beta-1bAlireza Minagar, Wanlong Ma, Xi Zhang, et al.
Pageof 4